Genome editing startup Edigene Inc. has raised RMB450 million ($67 million) in a series B financing round to move two of its programs for blood diseases into clinical trials. The financing round was led by 3H Health Investment, and supported by Sequoia Capital China, Alwin Capital and Kunlun Capital. Previous investors such as IDG Capital, Lilly Asia Venture, Huagai Capital and Green Pine Capital Partners also joined the round.
DUBLIN – The cash spigot is still turned on, as two more European firms disclosed series A rounds on Oct. 13. Chord Therapeutics SA took in €16 million (US$18.8 million) to repurpose cladribine for rare autoimmune disorders. Rappta Therapeutics Oy raised €9 million to take forward a novel concept in cancer, focused on developing small-molecule activators of protein phosphatase 2A (PP2A).
Astrazeneca plc said it has received about $486 million from the U.S. government to support the development and supply of a long-acting antibody combination under evaluation for the prevention and treatment of COVID-19. Phase III trials of the candidate, AZD-7442, are slated to begin later this month, the company told BioWorld. One trial will enroll more than 6,000 adults for the prevention of COVID-19 with additional trials set to enroll about 4,000 adults for the treatment of the infection, the Cambridge, U.K.-based company said.
DUBLIN – Priothera Ltd. closed a €30 million (US$35.4 million) series A round to shepherd an oral sphingosine 1 phosphate (S1P) receptor agonist through clinical development in patients with acute myeloid leukemia (AML) who are undergoing allogeneic hematopoietic stem cell transplantation (HSCT).
LONDON – Facing down the pandemic, U.K. biopharma had a record summer, raising just over £1 billion (US$1.3 billion) from June to August. That was up from £585 million in the second quarter of 2020, and brings the amount raised in the first nine months to £1.9 billion, putting 2020 on target to beat the 2018 record, when the annual total was £2.2 billion.
PERTH, Australia – Epi-Minder Pty. Ltd. has completed an oversubscribed series A round of AU$18 million (US$12.89 million) that will see its Minder epilepsy monitoring device enter a pivotal trial to support marketing applications in Europe and the U.S. The smartphone-enabled device promises to improve on wearables and other tools – such as patient diaries – that have proven to be unreliable.
BEIJING – Three-year-old startup Everest Medicines Ltd. (1952.HK) sold 63 million shares at HK$55 apiece to raise HK$3.49 billion (US$451 million) on the Hong Kong Stock Exchange on Oct 9. Shares were oversubscribed by 654 times in Hong Kong.
RSS
